eloralintide (LY3841136) / Eli Lilly - LARVOL DELTA

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=128 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Genetic Disorders • Obesity

Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Preclinical • Metabolic Disorders

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=188 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

P1 data • Metabolic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=96 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=250 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=1040 | Recruiting | Sponsor: Eli Lilly and Company | N=765 ➔ 1040

Enrollment change • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Recruiting | Trial completion date: Mar 2025 ➔ Oct 2025 | Trial primary completion date: Mar 2025 ➔ Oct 2025

Enrollment open • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=765 | Recruiting | Sponsor: Eli Lilly and Company | N=390 ➔ 765 | Trial completion date: Sep 2025 ➔ Aug 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Eli Lilly and Company | N=70 ➔ 128

Combination therapy • Enrollment change • Monotherapy • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3841136 in Healthy and Overweight Participants (clinicaltrials.gov) - P1 | N=148 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=225 | Recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Genetic Disorders • Obesity

A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=390 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: May 2025 ➔ Sep 2025 | Trial primary completion date: Nov 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=225 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of LY3841136 in Healthy and Overweight Participants (clinicaltrials.gov) - P1 | N=160 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2024 ➔ Jan 2024 | Trial primary completion date: Aug 2024 ➔ Jan 2024

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study of LY3841136 in Healthy and Overweight Participants (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Jan 2024 ➔ Aug 2024 | Trial primary completion date: Jan 2024 ➔ Aug 2024

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity